The Hospitalization Costs of Diabetes and Hypertension Complications in Zimbabwe: Estimations and Correlations.
Mutsa P MutowoPaula K LorgellyMichael LaxyAndre M N RenzahoJohn C MangwiroAlice J OwenPublished in: Journal of diabetes research (2016)
Objective. Treating complications associated with diabetes and hypertension imposes significant costs on health care systems. This study estimated the hospitalization costs for inpatients in a public hospital in Zimbabwe. Methods. The study was retrospective and utilized secondary data from medical records. Total hospitalization costs were estimated using generalized linear models. Results. The median cost and interquartile range (IQR) for patients with diabetes, $994 (385-1553) mean $1319 (95% CI: 981-1657), was higher than patients with hypertension, $759 (494-1147) mean $914 (95% CI: 825-1003). Female patients aged below 65 years with diabetes had the highest estimated mean costs ($1467 (95% CI: 1177-1828)). Wound care had the highest estimated mean cost of all procedures, $2884 (95% CI: 2004-4149) for patients with diabetes and $2239 (95% CI: 1589-3156) for patients with hypertension. Age below 65 years, medical procedures (amputation, wound care, dialysis, and physiotherapy), the presence of two or more comorbidities, and being prescribed two or more drugs were associated with significantly higher hospitalization costs. Conclusion. Our estimated costs could be used to evaluate and improve current inpatient treatment and management of patients with diabetes and hypertension and determine the most cost-effective interventions to prevent complications and comorbidities.
Keyphrases
- healthcare
- blood pressure
- type diabetes
- cardiovascular disease
- end stage renal disease
- palliative care
- chronic kidney disease
- glycemic control
- adipose tissue
- newly diagnosed
- quality improvement
- prognostic factors
- emergency department
- pain management
- chronic pain
- social media
- men who have sex with men
- wound healing
- neural network
- smoking cessation
- adverse drug